- Home
- CNNE vs MDXG Comparison
CNNE vs MDXG Comparison
Compare CNNE & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- MDXG
- Stock Information
- Founded
- CNNE 2014
- MDXG 2006
- Country
- CNNE United States
- MDXG United States
- Employees
- CNNE N/A
- MDXG N/A
- Industry
- CNNE Restaurants
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- MDXG Health Care
- Exchange
- CNNE Nasdaq
- MDXG Nasdaq
- Market Cap
- CNNE 1.1B
- MDXG 1.0B
- IPO Year
- CNNE N/A
- MDXG N/A
- Fundamental
- Price
- CNNE $18.47
- MDXG $7.42
- Analyst Decision
- CNNE Buy
- MDXG Strong Buy
- Analyst Count
- CNNE 2
- MDXG 3
- Target Price
- CNNE $22.50
- MDXG $12.00
- AVG Volume (30 Days)
- CNNE 474.5K
- MDXG 809.0K
- Earning Date
- CNNE 05-12-2025
- MDXG 04-30-2025
- Dividend Yield
- CNNE 2.60%
- MDXG N/A
- EPS Growth
- CNNE N/A
- MDXG N/A
- EPS
- CNNE N/A
- MDXG 0.27
- Revenue
- CNNE $452,500,000.00
- MDXG $352,375,000.00
- Revenue This Year
- CNNE N/A
- MDXG $9.23
- Revenue Next Year
- CNNE $2.23
- MDXG $11.49
- P/E Ratio
- CNNE N/A
- MDXG $27.33
- Revenue Growth
- CNNE N/A
- MDXG 5.34
- 52 Week Low
- CNNE $15.92
- MDXG $5.47
- 52 Week High
- CNNE $22.36
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- CNNE 58.77
- MDXG 59.64
- Support Level
- CNNE $17.66
- MDXG $6.53
- Resistance Level
- CNNE $18.24
- MDXG $7.07
- Average True Range (ATR)
- CNNE 0.37
- MDXG 0.30
- MACD
- CNNE 0.11
- MDXG 0.09
- Stochastic Oscillator
- CNNE 95.98
- MDXG 99.61
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.